Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

Summary

The main aim of this clinical trial is to find a way of giving ch14.18/CHO, in combination with subcutaneous aldesleukin (IL-2) and oral isotretinoin (13-cis-RA), to children and young people with primary refractory or relapsed neuroblastoma without intravenous morphine.

Conditions

• Neuroblastoma

Interventions

DRUG

ch14.18/CHO

DRUG

Aldesleukin

DRUG

Isotretinoin

Sponsors & Collaborators

• University Medicine Greifswald

  collaborator OTHER

• St. Anna Children's Hospital, Vienna

  collaborator UNKNOWN

• Hospital Universitario La Fe

  collaborator OTHER

• Istituto Giannina Gaslini

  collaborator OTHER

• Gustave Roussy, Cancer Campus, Grand Paris

  collaborator OTHER

• Schneider Children's Medical Center, Israel

  collaborator OTHER

• Great Ormond Street Hospital for Children NHS Foundation Trust

  collaborator OTHER

• University Hospital, Toulouse

  collaborator OTHER

• Johann Wolfgang Goethe University Hospital

  collaborator OTHER

• Jena University Hospital

  collaborator OTHER

• Children's University Hospital, Ireland

  collaborator OTHER

• University Hospital Tuebingen

  collaborator OTHER

• Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

  collaborator OTHER

• Alder Hey Children's NHS Foundation Trust

  collaborator OTHER

• University Hospitals Bristol and Weston NHS Foundation Trust

  collaborator OTHER

• Newcastle-upon-Tyne Hospitals NHS Trust

  collaborator OTHER

• The Leeds Teaching Hospitals NHS Trust

  collaborator OTHER

• NHS Greater Glasgow and Clyde

  collaborator OTHER

• Medical University of Graz

  collaborator OTHER

• Medical University Innsbruck

  collaborator OTHER

• Centre Leon Berard

  collaborator OTHER

• Hospital Infantil Universitario Niño Jesús, Madrid, Spain

  collaborator OTHER

• University Hospital Southampton NHS Foundation Trust

  collaborator OTHER

• Institut Curie

  collaborator OTHER

• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

  collaborator OTHER

• St. Anna Kinderkrebsforschung

  lead OTHER

Principal Investigators

• Holger Lode, MD, PhD · University Medicine Greifswald

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

1 Year

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-01-31

Primary Completion

2020-12-31

Completion

2020-12-31

Countries

• Austria
• France
• Germany
• Israel
• Italy
• Spain
• United Kingdom

Study Locations